"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study

Asian Institute of Gastroenterology, India

Status: Not yet enrolling

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)

Treatments: Procedure: A blood sample for CA 19-9 (cancer detection test)

Study type: Observational

Funder types: Other

Identifiers

NCT06044064

PDAC-NOD-001

Details and patient eligibility

About

To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes.

Purpose: To improve the rates of early detection of pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that starts in the pancreas, a gland located in your abdomen. It happens when some cells in the pancreas start growing abnormally and form a cancer.

Enrollment: 100 estimated patients

Sex: All

Ages: 50 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 50 years
• Patients diagnosed with diabetes based on FBS/ PPBS/ HbA1C
• Presence of atleast 1 FBS parameter measured in the past 6-18 months which was not > 125 mg/dl
• END-PDAC score > 2

Exclusion criteria

• Known or newly detected chronic pancreatitis
• Past history of pancreatic cancer
• History of steroid use
• Contraindications for EUS